SILVER SPRING, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients...
Aziyo Biologics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022
SILVER SPRING, Md., April 25, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients...
Aziyo Biologics Announces Upcoming KOL Call Hosted by Cowen – Call to Highlight the Use and Benefits of Aziyo’s CanGaroo Envelope for Implantable Electronic Devices
SILVER SPRING, Md., April 12, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients...
Aziyo Announces FDA 510(k) Submission for CanGaroo® RM, its Next-Generation Biomaterial Envelope Enhanced with Antibiotics
SILVER SPRING, Md., April 04, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), today announced the Company has filed a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for CanGaroo® RM Antibacterial...
Aziyo Biologics to Participate in the Lytham Partners Spring 2022 Investor Conference
SILVER SPRING, Md., March 31, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients...